CA2116575A1 - Adaptogenic agent - Google Patents

Adaptogenic agent

Info

Publication number
CA2116575A1
CA2116575A1 CA002116575A CA2116575A CA2116575A1 CA 2116575 A1 CA2116575 A1 CA 2116575A1 CA 002116575 A CA002116575 A CA 002116575A CA 2116575 A CA2116575 A CA 2116575A CA 2116575 A1 CA2116575 A1 CA 2116575A1
Authority
CA
Canada
Prior art keywords
valine
animals
organism
test
adaptogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002116575A
Other languages
English (en)
French (fr)
Inventor
Nonna Dmitrievna Kislyakova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2116575A1 publication Critical patent/CA2116575A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002116575A 1992-06-26 1993-06-28 Adaptogenic agent Abandoned CA2116575A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SU925049402A RU2038077C1 (ru) 1992-06-26 1992-06-26 Средство, обладающее адаптогенной активностью
RU5049402/14 1992-06-26

Publications (1)

Publication Number Publication Date
CA2116575A1 true CA2116575A1 (en) 1994-01-06

Family

ID=21607834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002116575A Abandoned CA2116575A1 (en) 1992-06-26 1993-06-28 Adaptogenic agent

Country Status (6)

Country Link
JP (1) JPH07500846A (ru)
AU (1) AU4591993A (ru)
CA (1) CA2116575A1 (ru)
HU (1) HUT71836A (ru)
RU (1) RU2038077C1 (ru)
WO (1) WO1994000116A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6227203B1 (en) 1998-02-12 2001-05-08 Medtronic, Inc. Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion
RU2451508C2 (ru) * 2010-04-05 2012-05-27 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Средство, стимулирующее физическую выносливость

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000411A1 (en) * 1980-07-31 1982-02-18 G Blackburn Novel amino acid preparation and therapy for treatment of stress and injury
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
CA2018137C (en) * 1989-06-14 2000-01-11 Thomas Scholl L-carnitine magnesium citrate

Also Published As

Publication number Publication date
HU9400574D0 (en) 1994-05-30
JPH07500846A (ja) 1995-01-26
RU2038077C1 (ru) 1995-06-27
HUT71836A (en) 1996-02-28
AU4591993A (en) 1994-01-24
WO1994000116A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
Korte et al. The many different faces of major depression: it is time for personalized medicine
Parkinson Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
US5767159A (en) Method of increasing creatine supply depot
Lindén Vitamin D and myocardial infarction
BENOWITZ et al. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man
Morrison A nutritional program for prolongation of life in coronary atherosclerosis
Coppen et al. Levodopa and L-tryptophan therapy in Parkinsonism
Langohr et al. Clomipramine and Metoprolol in Migraine Prophylaxis—A Double‐blind Crossover Study
Schroeder Pathogenesis of hypertension
Zahorska-Markiewicz et al. Adrenergic control of lipolysis and metabolic responses in obesity
Levine Histamine synthesis in man: inhibition by 4-bromo-3-hydroxybenzyloxyamine
US4761287A (en) Diabetes control by serotonin
Hammer et al. Gradual tolerance of metabolic activity is produced in mesolimbic regions by chronic cocaine treatment, while subsequent cocaine challenge activates extrapyramidal regions of rat brain
CA2116575A1 (en) Adaptogenic agent
EP0605742A1 (en) Agent with adaptogenic activity
Calkins et al. On piperidylmethyl-benzodioxane (933-F), hypertension, and pheochromocytoma
Thompson et al. The effect of iron deficiency on skeletal muscle metabolism of the rat
Brewerton et al. Testmeal responses following m-chlorophenylpiperazine and L-tryptophan in bulimics and controls
Minto et al. “Temposil” a new drug in the treatment of alcoholism
Simpson et al. Tyramine and new monoamine oxidase inhibitor drugs
Henquin et al. Nutritional monitoring and counselling for cancer patients during chemotherapy
JPH05262660A (ja) 三成分配合剤
Sodipo Acupuncture and blood studies in sickle-cell anemia
BEST et al. Effect of khellin on coronary artery insufficiency as evaluated by electrocardiographic tests
Humphreys North Arnerican ginseng and the stress response during acute exercise

Legal Events

Date Code Title Description
FZDE Dead